Washington, DC, July 09, 2018 --(PR.com
)-- The Medical Imaging & Technology Alliance (MITA) – the leading organization and collective voice of medical imaging equipment, radiopharmaceutical manufacturers, innovators, and product developers – today applauded the release of new research showing the effectiveness of high intensity focused ultrasound (HIFU) in treating patients with prostate cancer.
, which was published in European Urology, followed 625 medium to high risk nonmetastatic prostate cancer patients in the UK over a period of five years and found that the failure-free survival rate with HIFU can be equivalent to that of surgery but with fewer side effects. Fully 98 percent of men maintained pad-free urinary continence after their procedure and 85 percent maintained erectile function, according to the study’s results.
“These findings demonstrated how focused ultrasound contributes to better outcomes at lower costs and fewer patient complications, so men can continue to return to productive lives at home and at work,” said Patrick Hope, executive director of MITA. “This is a remarkable advancement in cancer care and we look forward to further developments in this treatment area and regulatory decisions that ensure men have access to this innovative treatment.”
The Medical Imaging & Technology Alliance (MITA), a division of NEMA, is the collective voice of medical imaging equipment manufacturers, innovators, and product developers. It represents companies whose sales comprise more than 90 percent of the global market for advanced medical imaging technology. For more information, visit www.medicalimaging.org. Follow MITA on Twitter @MITAToday.